Fresenius Medical Care vs Halozyme Therapeutics
Fresenius Medical Care (FMS), health care, and Halozyme Therapeutics (HALO), health care, side by side on market value, valuation, margins, balance sheet and price change. Higher and lower are marked; neither is called better.
Fresenius Medical Care is worth $11.3B on the stock market and Halozyme Therapeutics $10.9B: Fresenius Medical Care is valued at 3% more. Fresenius Medical Care trades at 12.5 times earnings and Halozyme Therapeutics at 24.0; operating margins in their latest fiscal years were 9.31% and 33.6%. Over the past year Fresenius Medical Care's share price has moved -4.75% and Halozyme Therapeutics's +37.7%.
Key facts
- Fresenius Medical Care market value
- $11.3B
- Halozyme Therapeutics market value
- $10.9B
- Fresenius Medical Care P/E
- 12.5
- Halozyme Therapeutics P/E
- 24.0
- Fresenius Medical Care revenue
- $21.8BFY to 2025-12-31
- Halozyme Therapeutics revenue
- $1.4BFY to 2025-12-31
- Superinvestors holding both
- 0
Market values as of .
| Measure | Fresenius Medical Care | Halozyme Therapeutics |
|---|---|---|
| Sector | Health Care | Health Care |
| Country | ||
| Fiscal year ends | 2025-12-31 | 2025-12-31 |
| Size | ||
| Market cap | $11.3Bhigher | $10.9Blower |
| Revenue | $21.8Bhigher | $1.4Blower |
| Earnings | $1.1Bhigher | $316.9Mlower |
| Employees | 106,291higher | 423lower |
| Total assets | $34.4Bhigher | $2.5Blower |
| Valuation | ||
| P/E | 12.5lower | 24.0higher |
| P/S | 0.5lower | 7.8higher |
| P/B | — | — |
| Dividend yield | — | 0.00% |
| Profitability | ||
| Operating margin | 9.31%lower | 33.6%higher |
| Balance sheet | ||
| Net assets | $14.8Bhigher | $48.8Mlower |
| Total liabilities | $18.6Bhigher | $2.5Blower |
| Total debt | $12Bhigher | $2.1Blower |
| Cash on hand | $1.8Bhigher | $133.8Mlower |
| Price change | ||
| Today | -0.78%lower | -0.55%higher |
| 1 year | -4.75%lower | +37.7%higher |
Market value, P/E, P/B, dividend yield and price changes are from live quotes (Yahoo Finance; prices may be delayed 15 minutes or more). Revenue, earnings, operating margin and the balance-sheet figures are from each company's latest annual report filed with the SEC (collected 2026-11-12); a company that reports in another currency is converted to US dollars at the exchange rate of that day. P/S sets today's market value against the latest fiscal year's revenue. “Higher” and “lower” compare the two numbers only; a higher P/E or more debt is not better. Dividend yield and P/B are shown only for companies based in the US. A dash means no figure is on file.
Which superinvestors hold them
From each tracked investor's latest 13F filing. A 13F lists long positions in US-listed shares at a quarter end, filed up to 45 days later.
Both (0)
None of the tracked investors.
Fresenius Medical Care only (3)
Halozyme Therapeutics only (5)
Percentages are each holding's share of that investor's reported portfolio. Who owns FMS · Who owns HALO
More on Fresenius Medical Care
Further comparisons
Fresenius Medical Care against its closest peers
Halozyme Therapeutics against its closest peers
Learn
Questions and answers
Which is bigger, Fresenius Medical Care or Halozyme Therapeutics?
By market value, Fresenius Medical Care is the larger: $11.3B against $10.9B for Halozyme Therapeutics. By revenue in its latest fiscal year, Fresenius Medical Care is the larger: $21.8B against $1.4B for Halozyme Therapeutics.
Which has the higher P/E ratio?
Halozyme Therapeutics: 24.0, against 12.5 for Fresenius Medical Care. A higher P/E means the market pays more for each dollar of the last twelve months' earnings; on its own it does not say which is the better value.
Which has the higher operating margin?
Halozyme Therapeutics: 33.6%, against 9.31% for Fresenius Medical Care. Operating margin is operating income as a share of revenue in the latest fiscal year.
Which has more debt?
Fresenius Medical Care: $12B, against $2.1B for Halozyme Therapeutics. Total debt is borrowings at the end of the latest fiscal year, as each company reported it; it is not set against cash here.
Which superinvestors own both Fresenius Medical Care and Halozyme Therapeutics?
None of the tracked superinvestors holds both in their latest 13F filing. 3 hold Fresenius Medical Care and 5 hold Halozyme Therapeutics.
Cite this page
Funkfolio, “Fresenius Medical Care vs Halozyme Therapeutics”, data as of 18 November 2026. https://funkfolio.com/compare/fms-vs-halo
Underlying data: Yahoo Finance quotes; SEC annual reports collected 2026-11-12; 13F filings.